Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus TAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus TAVIST.
CHILDREN'S ALLEGRA HIVES vs TAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Category C
Category C
Antihistamine
Antihistamine